company background image
A046

Panagene KOSDAQ:A046210 Stock Report

Last Price

₩3.70k

Market Cap

₩122.3b

7D

-8.0%

1Y

-40.6%

Updated

12 May, 2022

Data

Company Financials
A046210 fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health0/6
Dividends0/6

A046210 Stock Overview

Panagene Inc. develops products in the field of molecular diagnostics in South Korea.

Panagene Competitors

 

 

 

 

 

 

 

 

 

 

 

 

Price History & Performance

Summary of all time highs, changes and price drops for Panagene
Historical stock prices
Current Share Price₩3,700.00
52 Week High₩6,550.00
52 Week Low₩3,100.00
Beta0
1 Month Change-5.61%
3 Month Change-17.23%
1 Year Change-40.61%
3 Year Change-12.74%
5 Year Change-38.23%
Change since IPO-62.89%

Recent News & Updates

Shareholder Returns

A046210KR BiotechsKR Market
7D-8.0%-4.1%-3.3%
1Y-40.6%-34.3%-14.3%

Return vs Industry: A046210 underperformed the KR Biotechs industry which returned -34.3% over the past year.

Return vs Market: A046210 underperformed the KR Market which returned -14.3% over the past year.

Price Volatility

Is A046210's price volatile compared to industry and market?
A046210 volatility
A046210 Average Weekly Movement4.6%
Biotechs Industry Average Movement6.5%
Market Average Movement5.5%
10% most volatile stocks in KR Market10.4%
10% least volatile stocks in KR Market3.1%

Stable Share Price: A046210 is not significantly more volatile than the rest of KR stocks over the past 3 months, typically moving +/- 5% a week.

Volatility Over Time: A046210's weekly volatility (5%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1976n/aSung-Ki Kimhttps://www.panagene.com

Panagene Inc. develops products in the field of molecular diagnostics in South Korea. Its products include Liquid biopsy products for lung and colon cancers; tissue biopsy products for lung, thyroid, pancreatic, and colon cancers, as well as glioblastoma, myeloproliferative neoplasm, chronic myelogenous leukemia, central nervous system, myelofibrosis, and polycythemia vera diseases. The company also offers products for cervical cancer, sexually transmitted, and extreme drug resistance diseases; and peptide nucleic acid products.

Panagene Fundamentals Summary

How do Panagene's earnings and revenue compare to its market cap?
A046210 fundamental statistics
Market Cap₩122.28b
Earnings (TTM)-₩6.82b
Revenue (TTM)₩29.88b

0.0x

P/S Ratio

0.0x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
A046210 income statement (TTM)
Revenue₩29.88b
Cost of Revenue₩27.82b
Gross Profit₩2.06b
Other Expenses₩8.88b
Earnings-₩6.82b

Last Reported Earnings

Sep 30, 2013

Next Earnings Date

n/a

Earnings per share (EPS)0
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0.0%

How did A046210 perform over the long term?

See historical performance and comparison

Valuation

Is Panagene undervalued compared to its fair value and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • PE vs Industry

  • PE vs Market

  • PEG Ratio

  • PB vs Industry

In this section, we usually try to help investors determine whether Panagene is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Panagene has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.


Future Growth

How is Panagene forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


13.2%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Panagene has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Past Performance

How has Panagene performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


28.8%

Historical Pharmaceuticals & Biotech annual earnings growth

In this section we usually display a company’s past earnings and revenues to help investors visualise the trend through time. We also gauge the company’s performance by benchmarking its returns and growth to its industry peers and the wider market. However, Panagene has not provided sufficient past data to assess its track record.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have historical data.


Financial Health

How is Panagene's financial position?

Financial Health Score

0/6

Financial Health Score 0/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Debt Coverage

  • Interest Coverage

In this section we usually analyse Panagene's finance health to determine how well-positioned it is against times of financial distress, in particular, its ability to manage its cash and debt levels. Panagene has not provided adequate balance sheet data, its financial health cannot be properly assessed as it.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have financial information.


Dividend

What is Panagene current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate A046210's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate A046210's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if A046210's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if A046210's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as A046210 has not reported any payouts.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?


CEO

Sung-Ki Kim (60 yo)

no data

Tenure

Sung-Ki Kim serves as the Chief Executive Officer and President of Panagene Inc. Sung-Ki Kim serves as Executive Officer of Daedong Industrial Co., Ltd. Sung-Ki Kim graduated from Seoul National University...


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Panagene Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Panagene Inc.
  • Ticker: A046210
  • Exchange: KOSDAQ
  • Founded: 1976
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: ₩122.280b
  • Shares outstanding: 32.14m
  • Website: https://www.panagene.com

Number of Employees


Location

  • Panagene Inc.
  • 54, Techno 10-ro
  • Yuseong-gu
  • Daejeon
  • 34027
  • South Korea

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/05/12 00:00
End of Day Share Price2022/05/12 00:00
Earnings2013/09/30
Annual Earnings2012/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.